Dear Colleagues,

This issue is a continuation of the previous successful Special Issue “New Insights into Kinase Inhibitors”.

In the last 30 years, kinases have been widely studied as drug targets to inhibit proliferation and angiogenesis in cancer therapy. Kinase inhibitors now represent one of the major classes of chemotherapeutics, with 52 kinase inhibitors having been approved as anticancer agents.

To date, 538 kinases are found to be active in the human body, where they are responsible for the phosphorylation of up to one-third of the proteome in controlling migration, survival, proliferation, and other processes via phosphorylation cascades. Moreover, aberrant kinase activity has been described to have an important role not only in cancer but also in inflammatory, degenerative, immunological, metabolic, and cardiovascular diseases.

Although their druggability and clinical safety profile make kinases attractive targets, the majority of kinases are still unexplored, and the field of kinase inhibitors is still growing.

This Special Issue will highlight new insights into the discovery of new kinase inhibitors, from the investigation of new targets to the identification of novel small molecules. Contributions to this issue, both in the form of original articles or reviews, may focus on powerful strategies and technological advances in the synthesis of more efficient and selective compounds, new strategies to overcome kinase inhibitors resistance, and improvements regarding the use of kinase inhibitors in oncology and other pathologies, in which therapeutic combinations with less toxic and off-target effects are considered.

Dr. Roberta Bortolozzi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• kinase inhibitors
• kinase inhibitors chemistry
• therapy resistance
• combination therapy
• antitumoral activity

• New Insights into Kinase Inhibitors II in Molecules (1 article)
• New Insights into Kinase Inhibitors II in Molecules (1 article)